Neogen Corporation
Neogen Corporation (Nasdaq: NEOG) develops, manufactures and markets products and services for food and animal safety. Its Food Safety segment provides diagnostic test kits, culture media, consumables, instruments and software to food and feed producers and processors, laboratories, food service operators, and… From the company’s description.
Over the twelve months to Aug 31, 2026, Neogen Corporation reported revenue of $884.01M, down 0.3% from a year earlier, and a net loss of $56.14M. Its operating margin was −0.8%, and operations generated $85.25M in cash. In fiscal 2025, it reported revenue of $870.40M, down 2.7% from fiscal 2024, and a net loss of $7.90M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Neogen Corporation does
In the company’s own words
Neogen Corporation (Nasdaq: NEOG) develops, manufactures and markets products and services for food and animal safety. Its Food Safety segment provides diagnostic test kits, culture media, consumables, instruments and software to food and feed producers and processors, laboratories, food service operators, and regulatory agencies; offerings detect pathogens, toxins, allergens and sanitation indicators, as well as measure food quality and nutritional components. The Animal Safety segment serves livestock producers, veterinarians, researchers, distributors and companion animal owners with veterinary instruments, pharmaceuticals, vaccines, animal care products, rodent and insect controls, drug detection tests and genomics services. Products include Petrifilm and Reveal testing systems, Neogen Analytics software, veterinary instruments under the Ideal and Prima Tech brands, and pest-control products such as Ramik, CyKill, Havoc and Prozap. The company employs 2,636 people worldwide as of May 31, 2026, and customers outside the United States generated 51.2% of fiscal 2026 revenue. Neogen’s Genomics business is subject to a pending sale agreement. Its website is www.neogen.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Chemicals
- Headquarters
- LANSING, MI
- Fiscal year end
- May
- CIK
- 711377
- SIC
- 2835
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Neogen Corporation — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Neogen Corporation’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Neogen Corporation and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Neogen Corporation's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Neogen Corporation's last four quarterly filings that the numbers alone won't show?”